Dr Alphonce Liyoyo

Tanzania

EDCTP portfolio: Clinical Research & Development Fellowships

Dr Alphonce Liyoyo aims to specialise as an infectious disease clinical researcher with a view to further research in Tanzania.

Advocating a national fellowship programme

Dr Liyoyo is active as a researcher and clinician at the Kibong’oto Infectious Diseases Hospital in Tanzania and the challenge he has set for himself is to become a specialist in clinical research on infectious diseases. His objective and the fellowship reflect the wider challenge in sub-Saharan Africa, the relatively low rate of trained researchers that are able to compete for funding, inform policy-making and address national infectious disease challenges.

The challenge

Through the fellowship Dr Liyoyo seeks to boost hands-on skills and experience in the following areas: pharmacology, pharmacokinetics, and pharmacodynamics of old and new antibiotics for TB, TB/HIV and MDR-TB including those in early clinical phases and their interaction with other drugs. Secondly, he expanded his skills in designing a clinical research protocol, including developing the hypothesis, perform a literature review and submitting a proposal to regulatory and ethical review committees. To that end he also studies regulations of the Food and Drug Administration as well as Institutional Review Board policies.

After his placement at Novartis (Switzerland), he will retrun to the Kibong’oto Infectious Diseases Hospital and continue his career as a clinical researcher at the hospital. Besides further pursuing his own specialisation, he will teach, train, support and mentor junior scientists. He aims to mobilise research funding through teamwork and networking, nationally, regionally and internationally. Interestingly, he plans to disseminate his experience during the fellowship with a view to promoting fellowships as an instrument of capacity development. His approach comprises a peer-reviewed manuscript for publication; a short manuscript on capacity building and lessons learnt in an appropriate open access journal; a policy brief with recommendations specific to the Ministry of Health and Ministry of Science & Technology in Tanzania promoting a fellowship programme in the country; a press release for a general audience; and presentations at scientific conferences.

The project

Dr Liyoyo expects his fellowship will have impact at various levels: individually, at his home institution, the Kibong’oto Infectious Diseases Hospital, in a wider academic circle of students and colleagues, and perhaps at the level of national policymaking, through both the research supporting disease control and advocacy for a national fellowship programme.

Impact


test the safety and efficacy of this new formulation in young children

Bringing antiretroviral drugs to children

The CHAPAS trials have ensured that many more children with HIV have benefited
from life-saving antiretrovirals.

EDCTP portfolio: HIV & HIV-associated infections

The challenge

Dr Liyoyo is active as a researcher and clinician at the Kibong’oto Infectious Diseases Hospital in Tanzania and the challenge he has set for himself is to become a specialist in clinical research on infectious diseases. His objective and the fellowship reflect the wider challenge in sub-Saharan Africa, the relatively low rate of trained researchers that are able to compete for funding, inform policy-making and address national infectious disease challenges.

Through the fellowship Dr Liyoyo seeks to boost hands-on skills and experience in the following areas: pharmacology, pharmacokinetics, and pharmacodynamics of old and new antibiotics for TB, TB/HIV and MDR-TB including those in early clinical phases and their interaction with other drugs. Secondly, he expanded his skills in designing a clinical research protocol, including developing the hypothesis, perform a literature review and submitting a proposal to regulatory and ethical review committees. To that end he also studies regulations of the Food and Drug Administration as well as Institutional Review Board policies.

After his placement at Novartis (Switzerland), he will retrun to the Kibong’oto Infectious Diseases Hospital and continue his career as a clinical researcher at the hospital. Besides further pursuing his own specialisation, he will teach, train, support and mentor junior scientists. He aims to mobilise research funding through teamwork and networking, nationally, regionally and internationally. Interestingly, he plans to disseminate his experience during the fellowship with a view to promoting fellowships as an instrument of capacity development. His approach comprises a peer-reviewed manuscript for publication; a short manuscript on capacity building and lessons learnt in an appropriate open access journal; a policy brief with recommendations specific to the Ministry of Health and Ministry of Science & Technology in Tanzania promoting a fellowship programme in the country; a press release for a general audience; and presentations at scientific conferences.

The project

The later CHAPAS-3 trial compared the efficacy and safety of three fixed-dose combinations including two without stavudine (found to have some long-term side effects in adults, leading to a recommendation that its use be discontinued in children). The trial the first of its kind in Africa studied nearly 500 children at four sites in two African countries.

Dr Liyoyo expects his fellowship will have impact at various levels: individually, at his home institution, the Kibong’oto Infectious Diseases Hospital, in a wider academic circle of students and colleagues, and perhaps at the level of national policymaking, through both the research supporting disease control and advocacy for a national fellowship programme.

ratios forfixed-dose combinations and on appropriatedosage according to weight. 

The CHAPAS-3 trial confirmed the effectiveness of fixed-dose combinations, providing further impetus to the rollout of antiretrovirals to children. Its evidence on abacavir informed the WHO recommendation of abacavir-containing combinations for first-line therapy in children. Trial data have also been used to support applications for regulatory approval for new scored efavirenz tablets.

Impact

L’homme RF et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22(5):557–65.

Mulenga V et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIVinfected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2016;16(2):169–79.

WHO. Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2010.

WHO. Consolidated guidelines on the use of antiretroviral drugs
for treating and preventing

HIV infection: Recommendations for a public health approach
(second edition). 2016

Projects: Children with HIV in Africa Pharmacokinetics and Adherence of Simple Antiretroviral Regimens (CHAPAS): CHAPAS-1 and -3

Project lead: Professor Chifumbe Chintu, University Teaching Hospital, Zambia (CHAPAS-1); Dr Veronica Mulenga, University Teaching Hospital, Zambia (CHAPAS-3)

Target population(s): Children with HIV

Sample size: 71 (CHAPAS-1); 480 (CHAPAS-3)

Countries involved: Ireland, the Netherlands, the UK, the USA, Zambia (CHAPAS-1); Uganda, Zambia (CHAPAS-3)

Project duration: 2005–2009 (CHAPAS-1); 2010 –2011 (CHAPAS-3)

EDCTP funding: €1.2M (CHAPAS-1); €4.6M (CHAPAS-3)

Total project funding: €1.2M (CHAPAS-1); €5.0M

About us

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public–public partnership between 14 European and 16 African countries, supported by the European Union. EDCTP’s vision is to reduce the individual, social and economic burden of poverty-related infectious diseases by affecting sub-Saharan Africa. EDCTP’s mission is to accelerate the development of new or improved medicinal products for the identification, treatment and prevention of infectious diseases, including emerging and re-emerging diseases, through pre- and postregistration clinical studies, with emphasis on phase II and III clinical trials. Our approach integrates conduct of research with development of African clinical research capacity and networking. The second EDCTP programme is implemented by the EDCTP Association supported under Horizon 2020, the European Union’s Framework Programme for Research and Innovation.

Contact us

For more information, please contact us or leave a message using this form.
Please enter your name
Please enter a correct e-mail address
Please enter a comment
Thank you! Your message has been sent.
Something went wrong while submitting the form. Try again.

Share this publication

Forward this page by e-mail or share it directly on social media.

Search

Enter a search term to search the EDCTP publications.
Minimal length to search is 3 characters

This publication uses cookies

We use functional and analytical cookies to improve our website. In addition, third parties place tracking cookies to display personalised advertisements on social media. By clicking accept you consent to the placement of these cookies.